CardioLogical Solutions
http://www.cardiologicalsolutions.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CardioLogical Solutions
What’s New, And What’s Coming, In Radiopharmaceuticals
Novartis is the leader when it comes to targeted cancer therapies incorporating radioisotopes. But plenty of companies are trying to break in to this market.
ASCO-GI 2024 – Novartis Tightens Its Grip On The Radiopharmaceutical Space
Lutathera yields a 72% reduction in the risk of progression or death in first-line GEP-NETs trial.
Biopharma M&A Volume, Value Bounced Back Significantly In Q4
Acquisition activity in the biopharmaceutical sector saw a strong uptick in deal value and an exponential increase in total deal value during the fourth quarter, according to data from Evaluate.
Prostate Cancer Disappointment Means Lilly Might Finally Get The Point
Point Biopharma’s radiopharmaceutical lags Novartis’s on PFS, and its commercial viability may be limited.
Company Information
- Other Names / Subsidiaries
-
- Emboline, VasoStitch
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice